AI allows patients, doctors, and payers to make informed decisions based on evidence at a much faster pace.
Nancy Dreyer
Advertisement
Articles by Nancy Dreyer
Pharmaceutical Executive
Personalized medicines often come to market without much safety information. Small populations mean less data. Genzyme, for example, received FDA approval for Cerezyme, to treat Gaucher disease, based on a pivotal trial with only 30 patients.
Advertisement
Latest Updated Articles
Personalized Medicine Meets the Real WorldJune 1st 2006
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
3
What Governance Resets Should Pharma Companies Take in Response to AI?
4
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
5